In recent years, a class of drugs known as GLP-1 agonists have become wildly popular for patients seeking to lose weight
Eli Lillys tirzepatide (Mounjaro and Zepbound) is a GIP (glucose-dependent insulinotropic polypeptide)/GLP-1 dual agonist that is demonstrating excellent weight loss, type 2 diabetes management, as well as cardiovascular protection
Their reasons are varied and understandable
Initial effects like improved energy and skin clarity may appear within 2-4 weeks, but optimal cellular benefits typically emerge after 3 months of consistent use
Thats incredibly impactful: Losing 5% to 10% of your body weight is enough to improve blood pressure, cholesterol, and blood sugar
Molecular and Cellular Endocrinology, 432, 4455.